WHO WE ARE TEAM PORTFOLIO RESOURCES TissueTech Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in ophthalmology, optometry, orthopedics and wound care. The Company has pioneered stem cell research using human amniotic membrane to treat corneal surface conditions and developed Amniograft™, the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. The National Institute of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, 130,000 human implants have been conducted using the Company’s patented Crotek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform. Industry Sectors Exited, Healthcare Headquarters Doral, FL; Atlanta, GA Investment Status Exited Recent Company News RCCF Announces Sale of TissueTech Investment Jun 28, 2019 River Cities is pleased to announce the sale of our investment in TissueTech as part of a minority recapitalization of the company led by Essex Woodlands. Tiss... Read More TissueTech recruits Arnott for board Aug 04, 2017 TissueTech Inc. announced today that it has named John Arnott to its board of directors. Mr. Arnott was most recently Operating Partner and Executive Chairman o... Read More Amniox Medical Highlights Three Studies Demonstrating Effectiveness Of Umbilical Cord Tissue For Treating Chronic Wounds Apr 10, 2017 AMNIOX Medical, Inc., a TissueTech, Inc. company, highlighted the publication of three studies concerning NEOX CORD 1K, its cryopreserved human umbilical cord t... Read More AMNIOX Highlights Study Demonstrating Improved Outcomes in Patients Treated with CLARIX® Regenerative Matrix as an Adjunct to Lumbar Discectomy Oct 27, 2016 AMNIOX Medical, Inc., a TissueTech™, Inc., company, announced the results of a prospective randomized clinical study of its proprietary cryopreserved Amniotic... Read More Navigating the Value Analysis Committee Aug 24, 2016 No matter how groundbreaking or seemingly life-saving the medical technology, the criteria serving as the barrier between innovation and clinical utilization ar... Read More Home Who We Are Portfolio Resources Team Contact Us Get News & Updates Email © Copyright 2021 River Cities Capital | Cincinnati Web Design